Drug Design, Development and Therapy最新文献

{"title":"Mechanistic Exploration of Shugan Jianpi Formula for Treating Triple-Negative Breast Cancer Under Chronic Stress: A Network Pharmacology-Guided Experimental Study.","authors":"Fen Liu, Luning Li, Yiming Zhang, Jiaqi Zhang, Xinchen Tian, Dengtian Zhang, Ni Zhang, Tinghao Yan, Shulong Shi, Jianlin Wu, Shulong Jiang","doi":"10.2147/DDDT.S518123","DOIUrl":"10.2147/DDDT.S518123","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the pharmacological mechanisms of Shugan Jianpi Formula (SGJPF) in treating TNBC using network pharmacology and molecular biology approaches.</p><p><strong>Methods: </strong>HPLC/MS identified the key compounds in SGJPF. In vitro assays were performed on norepinephrine (NE)-stimulated MDA-MB-231 and SUM159PT cells to mimic triple-negative breast cancer (TNBC) under chronic psychological stress (CPS) and evaluate SGJPF's effects on cell proliferation, apoptosis, cell cycle, migration, and invasion. A TNBC mouse model exposed to CPS was used to assess SGJPF's influence on tumor growth. SGJPF's mechanisms were explored via network pharmacology and molecular docking, with target validation through Western blotting, immunohistochemistry, and immunofluorescence.</p><p><strong>Results: </strong>HPLC/MS analysis identified 806 compounds in SGJPF, including flavonoids, polyphenols, saponins, polysaccharides, alkaloids, terpenoids, coumarins, organic acids, and glycosides. Network pharmacology and molecular docking analyses identified SRC, ERK (MAPK1), and STAT3 as pivotal targets underlying the anti-tumor effects of SGJPF in TNBC. Both in vitro and in vivo experiments confirmed that SGJPF exerts its therapeutic effects through the modulation of the SRC/ERK/STAT3 signaling axis. In vitro, SGJPF effectively inhibited TNBC cell proliferation, migration, and invasion, while promoting apoptosis in NE-stimulated cells. In a CPS-induced TNBC mouse model, SGJPF significantly alleviated tumor progression, further corroborating its potential as a novel therapeutic strategy for TNBC.</p><p><strong>Conclusion: </strong>This study highlights the potential of SGJPF as a therapeutic strategy for TNBC through its modulation of the SRC/ERK/STAT3 signaling axis, offering a robust foundation for further investigation into its clinical application.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4585-4603"},"PeriodicalIF":4.7,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dolutegravir Derivatives Alleviate LPS-Induced Microglial Inflammation by Suppressing STAT1/3 Nuclear Translocation.","authors":"Lan Wang, Xiaoting Zhang, Yimian Wang, Longfei Mao, Xixi Hou, Lizeng Peng","doi":"10.2147/DDDT.S520724","DOIUrl":"10.2147/DDDT.S520724","url":null,"abstract":"<p><strong>Purpose: </strong>Microglial inflammation plays a significant role in a variety of neurological disorders. Dolutegravir as a antiretroviral drug has been reported to inhibit the secretion of pro-inflammatory cytokines. Meanwhile, compounds containing 1,2,3-triazole have shown potential anti-inflammatory properties. Therefore, this study aims to investigate the anti-inflammatory potential of dolutegravir-1,2,3-triazole structural derivatives and elucidate its associated mechanisms of action.</p><p><strong>Methods: </strong>Dolutegravir-1,2,3-triazole derivatives were synthesized through click chemistry reactions. The anti-inflammatory activity against microglial inflammation and cytotoxicity of these derivatives were evaluated using the Griess assay and MTT assay. In vitro, the effects of the compounds on the expression of inflammatory mediators in LPS-stimulated BV-2 microglial cells were assessed using Real-time PCR, ELISA, and Western blot. In vivo, the effects of the compounds on microglial inflammation and synaptic deficits in the hippocampus of LPS-challenged mice were evaluated using Real-time PCR, immunofluorescence, and Western blot.</p><p><strong>Results: </strong>We discovered compound <b>4k</b> exhibits the best inhibitory effect on microglial inflammation (IC₅₀ = 5.01 ± 0.57 μM) among the 27 dolutegravir derivatives. Compound <b>4k</b> significantly attenuates the expression of LPS-induced microglial M1 phenotype markers, NO, IL-1β, IL-6, TNF-α, iNOS, and COX-2, while concurrently enhancing the expression of M2 phenotype markers, IL-4 and Ym-1. Further mechanistic exploration has elucidated that compound <b>4k</b> modulates the polarization of microglia by suppressing the phosphorylation and nuclear translocation of STAT1/3 proteins. In the hippocampus of LPS-challenged mice, compound <b>4k</b> markedly diminishes the expression of the microglial activation marker Iba1 and inflammatory mediators IL-1β, TNF-α, and COX-2 which led to an enhancement in the expression of the synaptic protein synaptophysin, thereby mitigating the synaptic defects.</p><p><strong>Conclusion: </strong>Compound <b>4k</b> exerts significant anti-microglial inflammatory effects by modulating the STAT signaling pathway to alleviate synaptic defects, which offers promising avenues for developing innovative anti-microglial inflammatory treatment strategies.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4567-4584"},"PeriodicalIF":4.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Zanthoxyli Pericarpium-Zingiberis Rhizoma in the Treatment of Gastric Cancer Based on Network Pharmacology and Experimental Validation.","authors":"Qian Gu, Shuai Duan, Joanna Japhet Tibenda, Boyun Gou, Shicong Huang, Guoqing Chen, Na Ning, Yuhua Du, Wenjing Liu, Yi Nan, Ling Yuan","doi":"10.2147/DDDT.S503874","DOIUrl":"10.2147/DDDT.S503874","url":null,"abstract":"<p><strong>Background: </strong>Malignant tumors, as a major challenge in global public health, have posed a significant threat to human life and health. Although traditional chemotherapy can inhibit tumor growth, it is often associated with serious adverse effects and tolerance. Against this background, Chinese medicine therapies have gradually gained wide recognition, and they play an important role in the treatment of gastric cancer (GC). As the core combination of the traditional prescription \"Dajianzhong Tang\", the medicinal pair of Zanthoxyli Pericarpium and Zingiberis Rhizoma (ZP-ZR) has shown unique advantages in tumor treatment.</p><p><strong>Purpose: </strong>To explore the mechanism of action of ZP-ZR in the treatment of GC using network pharmacology, bioinformatics analysis and in vitro experimental validation, and to provide a theoretical basis for subsequent experimental studies.</p><p><strong>Patients and methods: </strong>Subsequently, the effects of ZP-ZR on the proliferative ability of gastric cancer HGC-27 and AGS cell lines were verified by CCK-8, apoptosis, cycle and colony formation assays. The effects of ZP-ZR on the metastatic ability of GC cells were evaluated by Wound healing, transwell cell invasion and transwell cell migration assays. In addition, we evaluated the expression of Hub genes, pathway proteins and mRNAs by Western blot and qRT-PCR.</p><p><strong>Results: </strong>ZP-ZR mainly regulated EGFR, PTGS2, MMP9, CXCL8, BCL2L1, CDK6, KIT target genes and PI3K/Akt pathway in GC for the treatment of gastric cancer. ZP-ZR inhibited the proliferation, induced apoptosis, blocked the cell cycle, and inhibited cell migration and invasion in AGS and HGC-27 cell lines. In addition, ZP-ZR affected the expression of PI3K-Akt-related proteins and decreased the mRNA expression of Hub genes.</p><p><strong>Conclusion: </strong>ZP-ZR treats GC through the PI3K-Akt pathway.The present study provides a new idea for further investigation of ZP-ZR in the treatment of GC.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4537-4566"},"PeriodicalIF":4.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.","authors":"Xuan Yu, Xinpeng Xu, Jing Wang, Zhao Wang, Yi Zhang","doi":"10.2147/DDDT.S519732","DOIUrl":"10.2147/DDDT.S519732","url":null,"abstract":"<p><strong>Background: </strong>The choice of anesthetic drugs is crucial in ambulatory surgery. Esketamine has anesthetic, analgesic, and sedative effects, but it is associated with dose-dependent psychiatric symptoms. Benzodiazepines can alleviate these symptoms, but traditional drugs like midazolam may prolong the recovery time. Remimazolam tosilate as a novel benzodiazepine, has not been fully explored in terms of its effects when combined with esketamine and its impact on psychiatric symptoms.</p><p><strong>Methods: </strong>A total of 249 patients undergoing elective laparoscopic surgery were enrolled. Randomly divided into the esketamine group (Group E), the esketamine plus midazolam group (Group EM), and the esketamine plus remimazolam tosilate group (Group ER). The primary outcome was the incidence of adverse reactions. The secondary outcomes included hemodynamics at different time points: at rest in the room (T0), immediately post-intubation (T1), immediately post-extubation (T2), 30 minutes following extubation (T3), and immediately after leaving the PACU (T4). Moreover, we also documented the Riker Sedation-Agitation Scale (SAS) scores at T2-4, as well as extubation time and PACU stay duration.</p><p><strong>Results: </strong>Patients in Group ER had a significantly lower incidence of postoperative diplopia and blurry vision compared to Groups E and EM (<i>p</i><0.05). Postoperative psychiatric symptoms were significantly lower in Groups EM and ER than in Group E (<i>p</i><0.05). At the T1 time point, Groups EM and ER displayed significantly lower MAP and HR, compared to Group E (<i>p</i><0.05). Groups E and ER displayed a shorter extubation time than Group EM (<i>p</i><0.05); the PACU stay of Group ER was shorter than those of Groups E and EM (<i>p</i><0.05). The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4527-4535"},"PeriodicalIF":4.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Explainable Artificial Intelligence in the Field of Drug Research.","authors":"Qingyao Ding, Rufan Yao, Yue Bai, Limu Da, Yujiang Wang, Rongwu Xiang, Xiwei Jiang, Fei Zhai","doi":"10.2147/DDDT.S525171","DOIUrl":"10.2147/DDDT.S525171","url":null,"abstract":"<p><p>In recent years, the widespread use of artificial intelligence (AI) and big data technologies in drug research has significantly accelerated the drug development process. However, their black-box nature makes it challenging to evaluate their effectiveness and safety. The interpretability of models has become a key issue in the application of AI in the drug development. In this paper, a bibliometric approach has been adopted to systematically analyze the application of Explainable Artificial Intelligence (XAI) techniques in drug research, with an in-depth discussion of the developmental trends, geographical distribution, journal preferences, major contributors, and research hotspots. In addition, the research results of XAI are summarized in the three directions of chemical, biological, and traditional Chinese medicine, and the future research directions and development trends are envisioned in order to promote the in-depth application of XAI technology in drug discovery and continuous innovation.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4501-4516"},"PeriodicalIF":4.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Preoperative Magnesium Sulphate Infusion on Emergence Agitation and Postoperative Quality of Recovery in Patients Undergoing Thoracoscopic Lobectomy.","authors":"Yutian Pu, Xingyu Geng, Maosan Wang, Gaochao Lv, Ziwei Hu, Can Fang, Xinyue Zhang, Wanting Li, Xiaoxuan Fan, Xiuxia Chen","doi":"10.2147/DDDT.S503714","DOIUrl":"10.2147/DDDT.S503714","url":null,"abstract":"<p><strong>Background: </strong>Emergence agitation(EA) is common in the early phase of recovery from general anesthesia in adults, which can potentially cause unpredictable harm to both patients and medical staff. This study aimed to examine the effects of preoperative magnesium sulphate infusion on emergence agitation and postoperative quality of recovery in patients undergoing thoracoscopic lobectomy.</p><p><strong>Patients and methods: </strong>84 patients undergoing thoracoscopic lobectomy were randomly assigned to either the magnesium sulphate group (group M) or the control group (group C). Group M received a 50 mg/ kg intravenous bolus of magnesium sulphate 20 minutes before induction, whereas group C was administered an equivalent volume of saline. The Riker Sedation-Agitation Scale (SAS) and the 40-item Quality of Recovery questionnaire (QoR-40) were used to evaluate emergence agitation and postoperative quality of recovery, respectively.</p><p><strong>Results: </strong>In comparison to group C, group M demonstrated a significantly lower incidence of EA (9.5% vs 42.9%; OR, 0.14; 95% CI, 0.04-0.47; <i>P</i> < 0.001) and dangerous agitation (0% vs 14.3%; OR, 2.17; 95% CI, 1.71-2.75; <i>P</i> =0.011), along with a reduction in the maximal SAS score (<i>P</i> < 0.05). Group M exhibited higher global QoR-40 scores than group C on postoperative day 1 (POD 1)(168.3±13.8 vs 155.6±16.5, <i>P</i><0.001). Additionally, group M displayed lower Numerical rating scale (NRS) pain scores both at rest and during coughing in PACU and on POD 1 (<i>P</i> < 0.001). There were no significant statistically differences between the two groups in terms of time to extubation, incidence of delayed recovery and residual sedation (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>Preoperative magnesium sulphate infusion effectively decreased the incidence and severity of EA in patients undergoing thoracoscopic lobectomy. Furthermore, it alleviated postoperative pain and improved postoperative quality of recovery, without an increase in adverse events.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4517-4525"},"PeriodicalIF":4.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Flavonoid Derivative of Icariside II (YS-10) Improves Erectile Dysfunction in a Diabetic Rat Model by Inhibiting Ferroptosis via Activation of the Nrf2/HO-1/GPX4 Pathway.","authors":"Yang Liu, Guan-Nan Liu, Ya-Rong Zha, Chen-Li Pan, Yong-de Xu, Hong-Wei Li, Yue-Yue Zang, Wan-Qi Wang, Jun-Jie Yao, Jun-Tao Sun, Yong Yang, Zhi-Tao Wei","doi":"10.2147/DDDT.S518992","DOIUrl":"10.2147/DDDT.S518992","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the therapeutic potential of YS-10, a novel flavonoid derivative of icariside II (ICA II), and to explore its mechanism of action in a diabetic rat model of erectile dysfunction (DMED).</p><p><strong>Methods: </strong>Twenty-four male Sprague-Dawley rats were divided into four groups: control, DMED, DMED + ICA II (2.5 mg/kg/day), and DMED + YS-10 (2.5 mg/kg/day). Treatments lasted for 4 weeks followed by a 3-day washout. Erectile function was assessed, and penile tissues were analyzed by histology, immunohistochemistry, ELISA, and Western blot. In vitro, primary corpus cavernosum endothelial cells (CCECs) were treated with advanced glycation end products (AGEs), YS-10, Fer-1 (ferroptosis inhibitor), or ML385 (Nrf2 inhibitor) to evaluate oxidative stress and ferroptosis.</p><p><strong>Results: </strong>In vivo, both YS-10 and ICA II (2.5 mg/kg/day) significantly improved erectile function in diabetic rats, increased smooth muscle content, reduced collagen deposition, and enhanced endothelial marker (CD31) expression in penile tissue (<i>p</i> < 0.01 vs DMED group). The maximum ICP/MAP ratio and oxidative stress markers were similarly restored in both treatment groups, with no significant difference between YS-10 and ICA II (<i>p</i> > 0.05). In vitro, YS-10 reversed AGEs-induced injury and ferroptosis in corpus cavernosum endothelial cells (CCECs), upregulated GPX4, downregulated ACSL4, and reduced ROS and lipid peroxidation, comparable to the effects of the ferroptosis inhibitor Fer-1. YS-10 also promoted Nrf2 nuclear translocation and elevated HO-1 expression. Molecular docking, immunofluorescence, and Western blotconfirmed the interaction between YS-10 and the Nrf2/HO-1/GPX4 signaling pathway.</p><p><strong>Conclusion: </strong>YS-10 improves erectile function in diabetic rats by reducing oxidative stress and inhibiting ferroptosis via activation of the Nrf2/HO-1/GPX4 pathway. At 2.5 mg/kg/day, YS-10 was effective, well-tolerated, and showed efficacy comparable to ICA II. These findings support its potential as a promising candidate for diabetes-related erectile dysfunction therapy.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4481-4500"},"PeriodicalIF":4.7,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Esketamine/Propofol and Sufentanil/Propofol on Intraoperative Hypoxemia During Bronchoscopy: A Randomized Trial.","authors":"Xiao Huang, Xueyang Li, Yuan Sun, Anshi Wu, Pan Ai","doi":"10.2147/DDDT.S490423","DOIUrl":"10.2147/DDDT.S490423","url":null,"abstract":"<p><strong>Purpose: </strong>Propofol and sufentanil are the most commonly used anesthetics during bronchoscopy. Esketamine is an s-enantiomer of ketamine racemate and has both sedative and analgesic effects, it does not inhibit respiration and maintains hemodynamic stability. We aimed to compare the intraoperative hypoxemia risk of esketamine/propofol with sufentanil/propofol for patients in bronchoscopy.</p><p><strong>Methods: </strong>This study was an investigator-initiated, single-center, randomized, double-blind clinical trial. Patients undergoing bronchoscopy were randomly assigned to receive either sufentanil group (n = 33; sufentanil: 0.2 μg/kg) or esketamine group (n = 33; esketamine: 0.2 mg/kg) for sedation and analgesia. Clinical data, anesthetics usage, incidence of intraoperative hypoxemia, total time of hypoxemia, recovery time, and adverse events were recorded.</p><p><strong>Main results: </strong>The incidence of intraoperative hypoxemia was significantly lower in the esketamine group than in the sufentanil group (27.2% vs 66.7%, <i>P</i>=0.001, OR=5.333, 95% CI=1.859-15.301). Propofol usage was significantly higher in the esketamine group than in the sufentanil group (t=2.952, <i>P</i>=0.004). The duration of hypoxia was significantly lower in the esketamine group than in the sufentanil group (Z=-3.445, <i>P</i><0.001), and the minimum oxygen saturation (SpO2) was significantly higher than in the sufentanil group (Z=-2.682, <i>P</i>=0.007). Recovery time from anesthesia was significantly lower in the esketamine group than in the sufentanil group (Z=-2.709, <i>P</i>=0.007). No difference was found in adverse reactions between the two groups.</p><p><strong>Conclusion: </strong>Esketamine combined with propofol reduced the incidence of intraoperative hypoxemia compared with sufentanil in bronchoscopy. Our results offer the possibility for a novel recommendation for the prevention of intraoperative hypoxemia during bronchoscopy. However, we mentioned the higher propofol use in the esketamine group. Additional clarification is necessary on the indications and the optimal dose of esketamine.</p><p><strong>Trial registration: </strong>Chinese clinical trial registry: ChiCTR2200058990.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4429-4436"},"PeriodicalIF":4.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Follicular Output Rate was Improved with 3-Day Letrozole Administration Compared with 5-Day Letrozole Administration Under Progestin-Primed Ovarian Stimulation.","authors":"Xiaoning Wang, Jiarong Tian, Liu Tian, Xin Chen, Zhenzhen Zhang, Honglu Diao, Ying Zhang","doi":"10.2147/DDDT.S521554","DOIUrl":"10.2147/DDDT.S521554","url":null,"abstract":"<p><strong>Purpose: </strong>Progestin-primed ovarian stimulation (PPOS) has been widely employed in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. In recent years, letrozole (LE) combined with medroxyprogesterone acetate (MPA) has been used in this protocol to enhance ovarian response. This study compared the effects of a 5-day regimen with those of a 3-day regimen of letrozole within PPOS, focused on the follicular output rate (FORT) and blastocyst formation rates.</p><p><strong>Patients and methods: </strong>From January 2017 to January 2020, 1,754 infertility patients who received PPOS protocol were divided into two groups: 577 patients received 2.5 mg/day LE for 5 days (LE 5-day), and 1177 patients received the same dose of LE for 3 days (LE 3-day). Propensity score matching (1:1) balanced confounders, yielding 489 patients per group. The primary outcoms was the FORT. The rate of blastocyst formation was evaluated as the secondary outcome. A multivariable logistic regression analysis was performed to compare the disparity in the FORT between the two groups.</p><p><strong>Results: </strong>After matching, the number of oocytes retrieved, number of mature oocytes, number of blastocysts, blastocyst formation rates, FORT, and clinical pregnancy rates were more favourable in the LE 3-day group than in the LE 5-day group (P < 0.05). In the multivariable linear regression model, after making adjustments for factors such as age, anti-Müllerian hormone (AMH), antral follicle count (AFC), body mass index (BMI), infertility type, and basal P, patients in the LE 3-day group exhibited an increase in the FOTR (β = 0.08, 95% confidence interval [CI] 0.02 to 0.14, P = 0.0082) and blastocyst formation rate (β = 0.23, 95% CI 0.17 to 0.29, P < 0.0001) compared to those in the LE 5-day group.</p><p><strong>Conclusion: </strong>Compared with LE administration for 5 days, LE administration for 3 days may increase the FORT and the rate of blastocyst formation.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4397-4406"},"PeriodicalIF":4.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Trends and Developments in Nanomaterials for Rheumatoid Arthritis: A Comprehensive Bibliometric Analysis.","authors":"Xuezhao Jia, Lei He, Yonglong Chang, Jiajie Li, Jing Wang, Xiaojun Zhang, Jinchen Guo","doi":"10.2147/DDDT.S514898","DOIUrl":"10.2147/DDDT.S514898","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is one of the common diseases associated with job loss and disability. However, the existing diagnosis and treatment methods are limited by factors such as misdiagnosis, missed diagnosis, and toxic side effects. In recent years, remarkable progress has been made in applying nanomedicine for RA treatment. However, previous studies lack a systematic and comprehensive analysis of the development trajectory of nanomaterials in the diagnosis and treatment of RA, the contributions of key researchers, and the evolution of research focuses. This study aims to fill this gap by providing a detailed bibliometric analysis of the global research landscape on nanomaterial applications in RA diagnosis and treatment, highlighting the significance of this field in advancing therapeutic interventions and identifying future research directions.</p><p><strong>Methods: </strong>Relevant literature on the application of nanomaterials in RA treatment was searched in the Web of Science Core Collection (WoSCC) database from January 1, 1985 to December 31, 2023. VOSviewer, CiteSpace, \"bibliometrix\" R-package, and Microsoft Office Excel 2021 were used for bibliometric analysis to evaluate the number of publications, research hotspots, main researchers, and institutions.</p><p><strong>Results: </strong>A total of 524 articles were included, involving 33 countries or regions, 784 institutions, and 2751 authors, covering 19 disciplines, including biochemistry and molecular biology, chemistry, engineering, immunology, and materials science. Countries with the highest publication output were China, India, and the United States, with China and the United States having the closest cooperation. The University of California at San Diego and CHEN X were the most influential institutions and authors. Journal of Controlled Release had the highest publication output and emerged as the most influential journal in the field. In recent years, research hotspots of nanomaterials in RA included \"dexamethasone\", \"micelle\", and \"diagnosis\".</p><p><strong>Conclusion: </strong>This study is the first comprehensive bibliometric analysis of nanotechnology in RA application. It highlights the importance of nanomaterials in advancing RA diagnosis and treatment and provides a valuable reference for future research. By identifying key research trends, influential contributors, and emerging hotspots, this analysis offers actionable insights for researchers to build upon, ultimately driving innovation and improving therapeutic outcomes in the field of nanomedicine for RA.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"4355-4371"},"PeriodicalIF":4.7,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}